2/15/2008

The overall survival of prostate cancer patients taking Dendreon's experimental vaccine Provenge appears to improve when they receive more potent doses of the drug, according to data the company released Thursday. Dendreon is trying to get FDA approval for the vaccine.

Full Story:
Forbes

Related Summaries